26S proteasome beta 1 and beta 2 catalytic subunits (26S proteasome β1/β2)

The 26S proteasome is a massive, ATP-dependent multi-subunit enzyme complex responsible for the degradation of the majority of intracellular proteins in eukaryotes (PubMed: 26151218). It consists of a 20S core particle, which contains the catalytic machinery, and 19S regulatory particles that recognize and unfold polyubiquitinated substrates (PubMed: 16890139). The 20S core features three distinct pairs of catalytic sites: beta 1 (caspase-like), beta 2 (trypsin-like), and beta 5 (chymotrypsin-like) (PubMed: 19116417). While the beta 5 subunit is the primary target of first-generation proteasome inhibitors like bortezomib, the beta 1 and beta 2 sites are increasingly recognized as critical therapeutic targets, particularly for overcoming drug resistance (PubMed: 21149454). Inhibition of these sites leads to the accumulation of misfolded proteins, triggering endoplasmic reticulum stress and the unfolded protein response, which ultimately induces apoptosis in malignant cells (PubMed: 22223747). This mechanism is particularly potent in hematological malignancies such as multiple myeloma and mantle cell lymphoma, where high protein synthesis rates create a heavy reliance on proteasomal clearance (PubMed: 15173881). Next-generation inhibitors like marizomib are designed to target all three catalytic sites (beta 1, beta 2, and beta 5) to achieve more comprehensive proteasome inhibition and improved clinical outcomes (PubMed: 19661381).

Other names

PSMB6 and PSMB7 catalytic sitesCaspase-like and trypsin-like proteasome subunits20S proteasome beta 1 and beta 2 subunitsProteasome subunit beta type-6 and type-7

Covalent or non-covalent inhibition of the N-terminal threonine (Thr1) active site of the beta 1 and beta 2 subunits, preventing the hydrolysis of peptide bonds in polyubiquitinated proteins (PubMed: 19116417, 22223747).